- Report
- February 2024
- 250 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Drug Pipelines
- April 2024
- 220 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- November 2023
- 115 Pages
United States
From €3619EUR$3,750USD£3,105GBP
- Report
- October 2022
- 270 Pages
Global
From €3619EUR$3,750USD£3,105GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2654EUR$2,750USD£2,277GBP
- Report
- September 2022
- 282 Pages
Global
From €9169EUR$9,500USD£7,866GBP
- Report
- January 2022
- 200 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Clinical Trials
- September 2021
- 60 Pages
Global
From €1448EUR$1,500USD£1,242GBP
- Report
- February 2021
- 118 Pages
Global
From €10612EUR$10,995USD£9,103GBP
- Drug Pipelines
- May 2018
- 79 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- April 2018
United States
From €7717EUR$7,995USD£6,619GBP
- Drug Pipelines
- August 2018
- 610 Pages
Global
From €21234EUR$22,000USD£18,215GBP
- Drug Pipelines
- July 2018
- 503 Pages
Global
From €21234EUR$22,000USD£18,215GBP
Orencia is a biologic drug used to treat immune disorders, such as rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. It is a recombinant human monoclonal antibody that works by blocking the activity of a protein called TNF-alpha, which is involved in the inflammation process. Orencia is administered via subcutaneous injection and is available in both a prefilled syringe and a vial.
Orencia is a relatively new drug, having been approved by the US Food and Drug Administration in 2005. It is currently marketed by Bristol-Myers Squibb, and is available in the United States, Canada, Europe, and other countries.
The Orencia market is highly competitive, with several other biologic drugs available to treat immune disorders. These include Humira, Enbrel, Remicade, and Simponi. In addition, there are several generic versions of Orencia available in some countries.
Companies in the Orencia market include Bristol-Myers Squibb, AbbVie, Pfizer, Merck, and Janssen Pharmaceuticals. Show Less Read more